GlaxoSmithKline PLC (GSK) Shares are Down -1.38%

GlaxoSmithKline PLC (GSK) : During the past 4 weeks, traders have been relatively bearish on GlaxoSmithKline PLC (GSK), hence the stock is down -3.17% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.73% relative to the S&P 500. The 4-week change in the price of the stock is -3.37% and the stock has fallen -1.38% in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 1.72% and the fifty day Moving Average is 0.72%. GlaxoSmithKline plc is up 3.03% in the last three month period. Year-to-Date the stock performance stands at 14.11%.

GlaxoSmithKline PLC (GSK) : The highest short term price target forecast on GlaxoSmithKline PLC (GSK) is $50 and the lowest target price is $49. A total of 2 equity analysts are currently covering the company. The average price of all the analysts is $49.5 with a standard deviation of $0.71.


GlaxoSmithKline PLC (NYSE:GSK): On Fridays trading session , Opening price of the stock was $43.79 with an intraday high of $44.19. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $43.43. However, the stock managed to close at $43.55, a loss of 0.43% for the day. On the previous day, the stock had closed at $43.74. The total traded volume of the day was 3,571,015 shares.

GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its human immunodeficiency virus (HIV) business is managed through ViiV Healthcare. GSKs Vaccines has a portfolio of over 30 paediatric, adolescent, adult travel vaccines. GSKs Established Products Portfolio includes over 50 off-patent products, as well as its branded generics business and other local products. The Consumer Healthcare business develops and markets products in four categories, such as wellness, oral health, nutrition and skin health. Its brands include Sensodyne, Panadol, Horlicks, Polident, Paradontax, Tums, ENO, NiQuitin/Nicorette, Abreva, Zovirax and Aquafresh. It operates in the United Kingdom, the United States, Belgium and China.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.